CROI 2015 Program and Abstracts

Keyword Index

On demand; 23LB Online; 1096

Phylodynamics; 236, 253 Phylogenetics; 127, 248, 250, 251, 252, 291 • Analysis; 109, 238 • Clusters; 253

Profibrotic factors; 796 PROBE-C study; 670 Progesterone; 860, 902 Prognostic; 316 Prognostic model; 1120 Prognostic score; 637 Program effectiveness; 158 Progression; 198 Progression of HAND; 465 Progressive multifocal leukoencephalopathy; 814 Proliferation; 107, 330 PROMISE; 31LB Prospective; 308, 560 Protease; 42, 588 Protease inhibitor; 551, 566, 582, 604, 644, 693, 699, 733 Proteome; 529 Proteomics; 287, 409 Providers; 974

Opportunistic infection; 836, 838, 917 Option B+; 865, 865, 873, 874, 875 Oral candidiasis; 844 Oral fluid; 635

Phylogeny; 230, 244, 247 Phylogeography; 229, 236

Oral mucosa; 897 Oral shedding; 716 Oral warts; 716 Oraquick; 635 Orphanhood; 1036 Outcomes; 718 Oxidative stress; 306, 501 – P – p21; 386 P2X; 323 P2X7 ATP receptors; 735 p6; 235 Paediatrics; 916 Panobinostat; 109

Physical activity; 489, 745, 804 PI-containing ARV regimens; 82 Pig tailed; 363 Placebo controlled; 139 Placenta; 898 Planned treatment interruption; 919 Plasma cells; 340 Plasma concentrations; 891 Plasma membrane; 45 Plasmacytoid dendritic cell; 186, 225 Platelet function; 732 Platelets; 736 PMTCT; 31LB, 32, 34, 533, 533, 863, 864, 866, 871, 878, 886, 908, 909 PMTCT and option B plus; 78 POC; 114LB

Proviral DNA; 35, 332 Proviral total DNA; 354 Pseudotyping; 214 Public health; 1024

Parathyroid hormone; 790 Parental sequences; 231 Partner notification; 1018, 1099, 1105 Partner services; 238, 1003, 1093

Point of care; 34, 614, 320, 630, 631 Point of care CD4 testing; 632LB, 1090 Policy; 160 Polymorphism; 226, 462, 611

Pulmonary tuberculosis; 817 Pulse wave velocity; 925, 926

Purinergic; 323 Pyroptosis; 202

Partner testing; 240 Passive infusion; 903 Pathogen-associated molecular pattern; 43 Pathogenesis; 366, 404, 811 Patient follow-up; 1077 Pattern recognition receptor; 43 PCR; 394, 616, 910 PCR free; 258 PCSK9; 731 PD-1; 300 PD1; 389LB Pediatric; 37, 700, 801, 871, 919, 927, 931, 934, 951, 954 • Adolescents; 38LB • ART; 914 • HIV; 921, 923, 937, 938, 940, 947 Peginterferon alpha; 695 Penicilliosis; 843 People who inject drugs; 1016, 1116 People who use drugs; 176 PEPFAR; 160 Peptide-MHC tetramer; 362 Pericardial fat; 744 Perinatal; 943 Perinatal HIV exposure; 936 Perinatal HIV infection; 334, 396, 922 Peripheral blood mononuclear cells (PBMCs); 81, 437 Peripheral neuropathy; 457 Persistence; 21, 105, 243, 381, 418, 425, 430, 983 Persistent replication; 706 Persons who inject drugs (PWID); 998 PET; 482 Phage display and rational design; 213 Pharmaceutical use; 1054 Pharmacodynamics; 114LB, 526, 528, 922LB Pharmacogenetics; 533, 515, 533, 791 Pharmacogenomics; 516, 517, 518 Pharmacokinetics; 82, 85LB, 532, 510, 512, 516, 517, 532, 650, 792, 887, 892, 893, 894, 922LB, 951 Pharmacologic measures; 514 Pharmacology; 436 PHI; 335, 377 Phosphate; 768 Phylodynamic analysis; 249

Pomalidomide; 87 Pooling; 616, 619 Pooling PCR; 704 Population; 1038 • Based; 1054

– Q – Q80K; 697 qEEG; 449 Quality of care (QoC); 561, 1077 Quality assurance; 634 Quantification; 421LB Quantitative digital PCR; 420 QUS; 776

• Based cohort; 159, 740 • Based intervention; 1093

• Effectiveness; 158 • Inference; 255, 255 • Level impact; 25, 158 • Viral load; 32, 153, 328, 1071 Postexposure prophylaxis (PEP); 957, 959, 957, 960, 961 Postpartum; 890, 899, 907

QVOA; 397 – R – Rab mediated; 543 Rab6A; 195 Raltegravir; 547, 552, 564, 594, 608, 891, 960 Random forest; 331 Randomised controlled trial; 94 Randomised double-blind placebo-controlled trial; 322 Randomised open-label trial; 779 Randomized controlled trial; 1091 Randomized trial; 137 Rapamycin; 415 Rapid diagnostic tests; 621, 629, 826, 1091, 1098 Rapid progressors; 338, 572 RCT; 22LB Re-engagement in Care; 854

Posttreatment control; 111LB, 377 Practice guidelines; 750, 658, 750 Pre-ART; 573, 1076 Prediction; 343 Predictive value of test; 628 Predictors; 469

Preexposure prophylaxis (PrEP); 8, 20, 22LB, 23LB, 24, 25, 86LB, 128, 514, 946, 962, 969, 970, 972, 973, 974, 975, 976, 977, 978LB, 979, 980, 981, 983, 984, 986, 988, 993, 1083, 1106, 1107, 1115, 1121, 1122 Pregnancy; 28, 85LB, 533, 864, 887, 888, 891, 892, 893, 894, 895, 899, 900, 901, 902, 907, 1108, 1122 Prenylation inhibition; 708LB PrePex; 1087 Preterm; 878 Prevalence; 452, 697, 856 Prevention; 56, 74, 1104, 157, 160, 734, 966LB, 971, 994, 1023, 1083, 1104 Prevention of mother-to-child transmission (PMTCT); 867, 870, 874, 875, 895, 1122 Primary • Care; 103LB, 666 • Cells; 187 • HIV infection; 62, 373, 383, 446, 475

Reinfection; 654 Relinkage; 1074 Reactivation; 395, 409 Readthrough transcripts; 384 REAF; 192, 192 Real-time PCR; 277 Real-time adherence monitoring; 8, 556, 559 Rebound virus; 112LB Recency of HIV Infection; 603, 625, 626, 627 Recombinants; 232 Recombination; 231, 257, 424 Record linkage; 724 Recreational substance use; 743 Rectal; 994 • Gels; 993

Keyword Index

• HIV-1 infection; 251 • Immune cells; 527 • Infection; 111LB Primer ID; 255, 593 Prisons; 807

689

CROI 2015